Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design (Q44178087)
Jump to navigation
Jump to search
scientific article published in October 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design |
scientific article published in October 2002 |
Statements
1 reference
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design (English)
1 reference
1 reference
Luigi Dogliotti
1 reference
Alfredo Berruti
1 reference
Alberto Bottini
1 reference
Raffaella Bitossi
1 reference
Gabriella Gorzegno
1 reference
Palmiro Alquati
1 reference
Andrea De Matteis
1 reference
Francesco Nuzzo
1 reference
Giorgio Giardina
1 reference
Saverio Danese
1 reference
Mario De Lena
1 reference
Vito Lorusso
1 reference
Antonio Farris
1 reference
Maria Giuseppa Sarobba
1 reference
Enza DeFabiani
1 reference
Giorgio Bonazzi
1 reference
Federico Castiglione
1 reference
Cesare Bumma
1 reference
Gregorio Moro
1 reference
Epirubicin-Lonidamine Group, Orbassano, Torino, Italy
1 reference
1 October 2002
1 reference
1 reference
Identifiers
1 reference